Needham & Company LLC Reaffirms “Buy” Rating for Immunocore (NASDAQ:IMCR)

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They currently have a $71.00 target price on the stock. Needham & Company LLC’s price target points to a potential upside of 141.74% from the stock’s current price.

Other equities analysts have also issued reports about the company. Mizuho lowered Immunocore from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $72.00 to $38.00 in a research note on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Monday, January 27th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Trading Down 0.7 %

Shares of NASDAQ:IMCR opened at $29.37 on Thursday. The company has a 50 day moving average of $30.08 and a 200-day moving average of $31.89. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.47 billion, a P/E ratio of -30.92 and a beta of 0.77. Immunocore has a twelve month low of $27.69 and a twelve month high of $72.05.

Institutional Investors Weigh In On Immunocore

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock worth $1,047,000 after purchasing an additional 420 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore in the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its position in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares during the period. Finally, Pier Capital LLC lifted its stake in Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after acquiring an additional 1,174 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.